𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical and angiographic performance of a new-generation modular stent design for treatment of de novo coronary lesions

✍ Scribed by Victor M. Legrand; Eulogio J. Garcia; Eberhard Grube; Khalife Khalife; Hans Bonnier; Philippe Commeau; Tadeusz Przewlocki; Carlos Macaya; Adam Witkowski

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
92 KB
Volume
54
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Eight-year clinical and angiographic fol
Eight-year clinical and angiographic follow-up after implantation of autologous arterial graft covered stent in a de novo thrombus-containing lesion
✍ Eleftherios Tsiamis; Konstantinos Toutouzas; Christodoulos Stefanadis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

In this case report, we present the clinical and angiographic follow-up 8 years after implantation of autologous arterial graft covered stent in a thrombus-containing lesion in the proximal segment of left anterior descending artery. The patient was asymptomatic after the implantation of the covered

Novel paclitaxel-eluting, biodegradable
Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry
✍ Paweł Buszman; Stanisław Trznadel; Krzysztof Milewski; Janusz Rzeźniczak; Tadeus 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract Objectives: The purpose of the present study was to evaluate the efficacy and safety of a biodegradable polymer coated, paclitaxel eluting stent (Luc‐Chopin^2^) based on 9‐months angiographic and 12‐months clinical follow‐up results. Background: First‐generation drug‐eluting stents util

Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat